TMED2-DT

Across TCGA pan-cancer cohorts, TMED2-DT RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated TMED2-DT data layer.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher TMED2-DT RNA is associated with worse overall survival. In most high-consensus cancer types, elevated TMED2-DT expression acts as an unfavorable survival marker, although some lineages such as BRCA and UCS show a favorable association.

KIRC, ACC, and COAD are the cancer types where TMED2-DT RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.516	0.706	<.001	117	view →
ACC	OS	Tertile	All	0.382	0.839	<.001	86	view →
COAD	OS	Quartile	III,IV	0.693	1.000	.001	47	view →
BRCA	OS	Quartile	III,IV	0.958	0.821	.006	47	view →
UCS	DFS	Median	IV	0.952	0.367	.001	46	view →
KICH	DFS	Tertile	II,III,IV	0.506	1.000	.007	43	view →
UVM	DFS	Quartile	III,IV	0.185	0.813	.004	41	view →
BLCA	OS	Tertile	All	0.592	0.324	.002	38	view →
LIHC	OS	Quartile	All	0.688	0.867	.007	31	view →
KIRP	DFS	Tertile	All	0.530	0.682	.005	18	view →
PRAD	DFS	Median	All	0.709	0.861	.001	18	view →
STAD	OS	Median	III,IV	0.655	0.381	.024	16	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

TMED2-DT–KIRC (OS)

Open the KIRC breakdown →